StockData
Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd (RDY) stock

RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.98+0.19 (+1.28%)

Close on Nov 18, 2026Market cap $12.50BP/E 27.5Yield 0.57%

Dr Reddys Laboratories revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2026 it was ₹335.93B, up 3.2% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is ₹335.93B in fiscal 2026.

Annual revenue

PeriodPeriod endValueChange
FY2026Mar 31, 2026₹335.93B+3.2%
FY2025Mar 31, 2025₹325.54B+16.6%
FY2024Mar 31, 2024₹279.16B+13.5%
FY2023Mar 31, 2023₹245.88B+14.7%
FY2022Mar 31, 2022₹214.39B+13.0%
FY2021Mar 31, 2021₹189.72B+8.7%
FY2020Mar 31, 2020₹174.60B+13.5%
FY2019Mar 31, 2019₹153.85B+8.3%
FY2018Mar 31, 2018₹142.03B+0.9%
FY2017Mar 31, 2017₹140.81B-9.0%
FY2016Mar 31, 2016₹154.71B–

More Dr Reddys Laboratories figures

See a number that looks wrong?